For the Inventor, By the Inventor

Enter assignee name

Palo Alto, CA, United States of America

Eiger Biopharmaceuticals, Inc.

USPTO Granted Patents = 13

EPO Patents = 3

Trademarks = 3

Forward Citations = 39

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

David A Cory (6 out of 7 patents)

Xiaofeng Xiong (6 out of 6 patents)

Jeffrey S Glenn (4 out of 36 patents)

4. Ingrid Choong (4 out of 17 patents)

5. Debra Odink (2 out of 3 patents)

6. Christine M N Smith (2 out of 2 patents)

7. Tracey L McLaughlin (2 out of 10 patents)

8. Colleen M Craig (2 out of 10 patents)

9. Patrick Gosselin (2 out of 2 patents)

10. Aimesther Betancourt (2 out of 2 patents)

11. Eduardo Bruno Martins (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 12029819 - Pharmaceutical compositions comprising lonafarnib and ritonavir (2024-07-09),

2. 11793793 - Treatment of hepatitis delta virus infection (2023-10-24),

3. 11738086 - Methods of using buffered formulations of exendin (9-39) (2023-08-29),

4. 11571403 - Methods for the treatment of non-alcoholic steatohepatitis (2023-02-07),

5. 11517532 - Methods of treating hepatitis delta virus infection (2022-12-06),

6. 11311519 - Treatment of hepatitis delta virus infection (2022-04-26),

7. 11116820 - Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives (2021-09-14),

8. 11020484 - Buffered formulations of exendin (9-39) (2021-06-01),

9. 10953072 - Treatment of hepatitis delta virus infection with interferon lambda (2021-03-23),

10. 10828283 - Treatment of hepatitis delta virus infection (2020-11-10),

11. 10653753 - Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives (2020-05-19),

12. 10588880 - Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis (2020-03-17),

13. 10076512 - Treatment of hepatitis delta virus infection (2018-09-18),

Eiger Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. The company's pipeline includes innovative treatments for hepatitis delta virus, pulmonary arterial hypertension, and lymphedema. Eiger is committed to delivering potentially life-changing therapies to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

13 Patents

#142 in Palo Alto, CA

#5,494 in California

#23,162 in US

#43,712 in the World

Palo Alto, CA, United States of America

Eiger Biopharmaceuticals, Inc.

Forward Citations = 39

11 inventors:

David A Cory (6 out of 7 patents)

Xiaofeng Xiong (6 out of 6 patents)

Jeffrey S Glenn (4 out of 36 patents)

4. Ingrid Choong (4 out of 17 patents)

5. Debra Odink (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…